Multivessel Primary PCI May Be Beneficial in STEMI with Shock

In extremely ill patients with multivessel disease, 6-month survival was significantly better after multivessel revascularization than after culprit-vessel–only revascularization.

Most experts advocate an aggressive revascularization strategy in patients with ST-segment-elevation myocardial infarction (STEMI) who experience cardiogenic shock, cardiac arrest, or both; however, evidence supporting multivessel (MV) percutaneous coronary intervention (PCI) in this setting is lacking. In this prospective, multicenter, French study, investigators assessed 6-month survival in 169 patients with MV coronary artery disease (mean age, 67; 73% men) who presented with STEMI, resuscitated cardiac arrest, and shock. Most patients (61%) underwent culprit-vessel–only stenting.

Baseline characteristics were similar in patients who underwent culprit-vessel–only PCI and those who underwent MV PCI. In the MV-PCI group, the mean number of …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI